LUP Statistics
Record
- Title
- Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
- Type
- Journal Article
- Publ. year
- 2015
- Author/s
- Gimsing, P; Hjertner, Ø; Abildgaard, N; Andersen, N F et al.
- Department/s
- Division of Hematology and Transfusion Medicine
- In LUP since
- 2016-04-01
Downloads
Total | This Year | This Month |
327 | 10 | 1 |
United States of America | 166 (51%) |
Germany | 110 (34%) |
France | 8 (2%) |
China | 8 (2%) |
Singapore | 4 (1%) |
Russian Federation | 4 (1%) |
Ireland | 3 (1%) |
United Kingdom of Great Britain and Northern Ireland | 3 (1%) |
Canada | 3 (1%) |
Netherlands (Kingdom of the) | 3 (1%) |
Sweden | 2 (1%) |
India | 2 (1%) |
Bulgaria | 2 (1%) |
Taiwan (China) | 1 (0%) |
Czechia | 1 (0%) |
New Zealand | 1 (0%) |
Italy | 1 (0%) |
Hong Kong (China) | 1 (0%) |
South Korea | 1 (0%) |
Nigeria | 1 (0%) |
Turkiye | 1 (0%) |